Trials / Active Not Recruiting
Active Not RecruitingNCT04869137
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
Neoadjuvant Lenvatinib Plus Pembrolizumab in Resectable Merkel Cell Carcinoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm trial of participants with Merkel cell carcinoma receiving a combination of lenvatinib plus pembrolizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib Oral Product | 20mg of Lenvatinib will be taken orally once daily |
| DRUG | Pembrolizumab | 200mg of Pembrolizumab will be administered through IV infusion every 3 weeks. |
Timeline
- Start date
- 2021-05-28
- Primary completion
- 2025-09-13
- Completion
- 2026-09-01
- First posted
- 2021-05-03
- Last updated
- 2026-04-08
- Results posted
- 2026-04-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04869137. Inclusion in this directory is not an endorsement.